Comprehensive Review of Obesity Drugs Including GLP-1 Agonists and Emerging Peptide Therapies
This review covers all five approved obesity drugs and emerging peptide-based therapies including GLP-1 analogs, dual/triple agonists, amylin mimetics, leptin analogs, and ghrelin antagonists.
Quick Facts
What This Study Found
Emerging peptide-based obesity therapies, particularly GLP-1 analogs and unimolecular dual/triple agonists targeting GLP-1, GIP, and glucagon receptors, show encouraging preclinical and early clinical results for weight loss.
Key Numbers
GLP-1 agonists produced clinically meaningful weight loss; weight regain common upon discontinuation.
How They Did This
Narrative review of published literature on approved obesity pharmacotherapies and emerging drug mechanisms, including preclinical and early clinical trial data.
Why This Research Matters
Obesity is a growing global health crisis with limited effective drug options. Understanding the full pipeline of peptide-based therapies helps contextualize the rapid advances in this field and the potential for transformative new treatments.
The Bigger Picture
This 2020 review captures a pivotal moment in obesity pharmacotherapy, just before the explosive growth of GLP-1 agonists like semaglutide and tirzepatide. Many of the 'emerging' therapies discussed have since entered or advanced through clinical trials, validating the peptide-based approach to obesity treatment.
What This Study Doesn't Tell Us
Review published in 2020, before the landmark results of semaglutide and tirzepatide for obesity. Some discussed therapies may have since been discontinued or advanced significantly. Narrative review format lacks systematic methodology.
Questions This Raises
- ?Which of the emerging dual/triple agonists will prove most effective and tolerable in large-scale trials?
- ?Can peptide-based obesity drugs maintain weight loss long-term without continued use?
- ?How will the cost and accessibility of these therapies affect their public health impact?
Trust & Context
- Key Stat:
- 5 approved drugs available for obesity treatment at time of review, with multiple peptide-based candidates in the pipeline
- Evidence Grade:
- Narrative review summarizing evidence across multiple drug classes. Individual therapies discussed range from approved to early preclinical.
- Study Age:
- Published in 2020, before semaglutide's obesity approval and tirzepatide's emergence. The peptide therapy landscape has advanced dramatically since.
- Original Title:
- Drug Therapy in Obesity: A Review of Current and Emerging Treatments.
- Published In:
- Diabetes therapy : research, treatment and education of diabetes and related disorders, 11(6), 1199-1216 (2020)
- Authors:
- Williams, David M(2), Nawaz, Asif, Evans, Marc(4)
- Database ID:
- RPEP-05200
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What are dual and triple agonists for obesity?
These are single molecules designed to activate multiple hormone receptors simultaneously — such as GLP-1 plus GIP, or GLP-1 plus GIP plus glucagon — potentially achieving greater weight loss than targeting one receptor alone.
Why are gut hormones important for obesity treatment?
Gut hormones naturally regulate appetite, satiety, and metabolism. Peptide drugs that mimic or block these hormones can help control hunger and energy balance more effectively than traditional approaches.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05200APA
Williams, David M; Nawaz, Asif; Evans, Marc. (2020). Drug Therapy in Obesity: A Review of Current and Emerging Treatments.. Diabetes therapy : research, treatment and education of diabetes and related disorders, 11(6), 1199-1216. https://doi.org/10.1007/s13300-020-00816-y
MLA
Williams, David M, et al. "Drug Therapy in Obesity: A Review of Current and Emerging Treatments.." Diabetes therapy : research, 2020. https://doi.org/10.1007/s13300-020-00816-y
RethinkPeptides
RethinkPeptides Research Database. "Drug Therapy in Obesity: A Review of Current and Emerging Tr..." RPEP-05200. Retrieved from https://rethinkpeptides.com/research/williams-2020-drug-therapy-in-obesity
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.